Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment
- PMID: 38690275
- PMCID: PMC11058664
- DOI: 10.3389/fimmu.2024.1340702
Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment
Abstract
The extracellular matrix (ECM) is a complex three-dimensional structure composed of proteins, glycans, and proteoglycans, constituting a critical component of the tumor microenvironment. Complex interactions among immune cells, extracellular matrix, and tumor cells promote tumor development and metastasis, consequently influencing therapeutic efficacy. Hence, elucidating these interaction mechanisms is pivotal for precision cancer therapy. T lymphocytes are an important component of the immune system, exerting direct anti-tumor effects by attacking tumor cells or releasing lymphokines to enhance immune effects. The ECM significantly influences T cells function and infiltration within the tumor microenvironment, thereby impacting the behavior and biological characteristics of tumor cells. T cells are involved in regulating the synthesis, degradation, and remodeling of the extracellular matrix through the secretion of cytokines and enzymes. As a result, it affects the proliferation and invasive ability of tumor cells as well as the efficacy of immunotherapy. This review discusses the mechanisms underlying T lymphocyte-ECM interactions in the tumor immune microenvironment and their potential application in immunotherapy. It provides novel insights for the development of innovative tumor therapeutic strategies and drug.
Keywords: T lymphocytes; extracellular matrix; immune escape; targeted therapy; tumor microenvironment.
Copyright © 2024 Lv, Fei, Chen, Wang, Han, Cui, Feng, Zhang and Chen.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Biomaterials to regulate tumor extracellular matrix in immunotherapy.J Control Release. 2024 Dec;376:149-166. doi: 10.1016/j.jconrel.2024.10.010. Epub 2024 Oct 11. J Control Release. 2024. PMID: 39389365 Review.
-
CAFs and T cells interplay: The emergence of a new arena in cancer combat.Biomed Pharmacother. 2024 Aug;177:117045. doi: 10.1016/j.biopha.2024.117045. Epub 2024 Jul 1. Biomed Pharmacother. 2024. PMID: 38955088 Review.
-
Protease regulation of tumor-immune cell symbiosis.Trends Cancer. 2025 Jun;11(6):560-574. doi: 10.1016/j.trecan.2025.02.004. Epub 2025 Mar 8. Trends Cancer. 2025. PMID: 40057434 Review.
-
Role of cell surface proteoglycans in cancer immunotherapy.Semin Cancer Biol. 2020 May;62:48-67. doi: 10.1016/j.semcancer.2019.07.012. Epub 2019 Jul 20. Semin Cancer Biol. 2020. PMID: 31336150 Review.
-
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.J Immunother Cancer. 2018 Jul 3;6(1):65. doi: 10.1186/s40425-018-0376-0. J Immunother Cancer. 2018. PMID: 29970158 Free PMC article. Review.
Cited by
-
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma.Cell Oncol (Dordr). 2024 Oct;47(5):1561-1578. doi: 10.1007/s13402-024-00970-6. Epub 2024 Jul 15. Cell Oncol (Dordr). 2024. PMID: 39008192 Review.
-
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.Signal Transduct Target Ther. 2025 Jul 31;10(1):227. doi: 10.1038/s41392-025-02280-1. Signal Transduct Target Ther. 2025. PMID: 40739089 Free PMC article. Review.
-
Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review.Pharmaceuticals (Basel). 2025 Jul 22;18(8):1082. doi: 10.3390/ph18081082. Pharmaceuticals (Basel). 2025. PMID: 40872475 Free PMC article. Review.
-
Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review).Int J Mol Med. 2025 Jul;56(1):104. doi: 10.3892/ijmm.2025.5545. Epub 2025 May 9. Int J Mol Med. 2025. PMID: 40342021 Free PMC article. Review.
-
Tumor secretome shapes the immune landscape during cancer progression.J Exp Clin Cancer Res. 2025 Feb 10;44(1):47. doi: 10.1186/s13046-025-03302-0. J Exp Clin Cancer Res. 2025. PMID: 39930476 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials